Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is the first study of oral tofacitinib in adults with active ankylosing spondylitis. It is designed to obtain information on the efficacy and safety of 3 different doses of tofacitinib.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

• Documented diagnosis of Ankylosing Spondylitis

• Has active disease despite concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) treatment or is intolerant to NSAIDs

Exclusion Criteria:

• Pregnant or lactating females

• Currently receiving or previous use of a Tumor Necrosis Factor (TNF) inhibitor or any biological agent